Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
02359 WUXI APPTEC
RTNominal down167.700 -1.400 (-0.828%)
Research Report

30/04/2021 17:17

{I-bank focus}GS raises Wuxi Apptec (02359) to HK$227.6

[ET Net News Agency, 30 April 2021] Goldman Sachs raised its target price for Wuxi
Apptec (02359) to HK$227.6 from HK$202.3 and maintained its "buy" rating.
The research house said it sees the accelerated 1Q growth further validating its
constructive view on the company as a global pharma/biotech innovation enabler. It views
the strong growth momentum to continue in 2021 and see the company's new capabilities
expansion (e.g. AAC vector suspension platform) to drive mid-to-long term growth. (RC)

Remark: Real time quote last updated: 22/10/2021 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.